Company News
Ultragenyx Shares Rise 14% After FDA Approval
Ultragenyx’s stock jumped about 14% in after‑hours trading following the FDA’s accelerated approval of GENGLYCOS, its first gene‑therapy product.
GENGLYCOS (DTX401) is approved for patients eight year
